Search research articles
Contact Us
Filters
Showing results (1-10 of 38) with videos related to
Page
of 4
Sort By:
Clinical Advances in Hematology & Oncology : H&O
|
April 9, 2016
Adjuvant treatment for patients with surgically resected advanced-stage melanoma
Kenneth F Grossmann
Therapeutic Advances in Medical Oncology
|
December 18, 2015
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications
Kenneth F Grossmann, Kim Margolin
Parkinsonism & Related Disorders
|
July 7, 2014
Sustained remission of Parkinson disease associated melanoma with immunotherapy
David R Shprecher, Kenneth F Grossmann, Jonathan D Tward
Diagnostic Cytopathology
|
May 24, 2012
Molecular testing in malignant melanoma
Allie H Grossmann, Kenneth F Grossmann, Michelle L Wallander
Annals of Translational Medicine
|
July 19, 2021
The dark side of immunotherapy
Nwanneka Okwundu, Douglas Grossman, Siwen Hu-Lieskovan, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
May 20, 2020
Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies
Kelsey Baron, Justin C Moser, Shiven Patel, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 11, 2020
Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma
Justin C Moser, Guo Wei, Sarah V Colonna, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 1, 2016
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)
Christopher J Anker, Kenneth F Grossmann, Michael B Atkins, et al.
Journal of Neurosurgery
|
March 14, 2015
Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment
David Ly, Hilary P Bagshaw, Christopher J Anker, et al.
Cancer Medicine
|
November 3, 2019
Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab
Justin C Moser, Danli Chen, Siwen Hu-Lieskovan, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 38) with videos related to
Sort By:
Page
of 4
Clinical Advances in Hematology & Oncology : H&O
|
April 9, 2016
Adjuvant treatment for patients with surgically resected advanced-stage melanoma
Kenneth F Grossmann
Therapeutic Advances in Medical Oncology
|
December 18, 2015
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications
Kenneth F Grossmann, Kim Margolin
Parkinsonism & Related Disorders
|
July 7, 2014
Sustained remission of Parkinson disease associated melanoma with immunotherapy
David R Shprecher, Kenneth F Grossmann, Jonathan D Tward
Diagnostic Cytopathology
|
May 24, 2012
Molecular testing in malignant melanoma
Allie H Grossmann, Kenneth F Grossmann, Michelle L Wallander
Annals of Translational Medicine
|
July 19, 2021
The dark side of immunotherapy
Nwanneka Okwundu, Douglas Grossman, Siwen Hu-Lieskovan, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
May 20, 2020
Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies
Kelsey Baron, Justin C Moser, Shiven Patel, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 11, 2020
Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma
Justin C Moser, Guo Wei, Sarah V Colonna, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 1, 2016
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)
Christopher J Anker, Kenneth F Grossmann, Michael B Atkins, et al.
Journal of Neurosurgery
|
March 14, 2015
Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment
David Ly, Hilary P Bagshaw, Christopher J Anker, et al.
Cancer Medicine
|
November 3, 2019
Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab
Justin C Moser, Danli Chen, Siwen Hu-Lieskovan, et al.
Page
of 4